stockrow
Friday 6 November 2026
Export ORGO’s income statement to Excel — free account
Organogenesis
ORGO Healthcare Drug Manufacturers Specialty & Generic
Organogenesis' revenue for fiscal 2025 (year ended December 2025) was $564.2 million, up 17.0% from fiscal 2024.
- Revenue
- −69.9%
- EPS
- −327.3%
- Free cash flow
- −2,048.8%
- Total debt
- +395.3%
Quarter to September 2026, against a year earlier
0.89
0.05
+5.95%
Follow ORGO
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
57.56 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.16 | 0.59 | 0.68 | 0.50 | |
P/FCF ratio |
0.00 | 17.73 | 15.00 | 49.81 | |
P/Operating CF |
16.65 | 14.34 | (9.88) | (9.50) | |
P/B ratio |
2.19 | 1.24 | 2.11 | 1.48 | |
Price to Tangible BV |
2.50 | 1.43 | 2.68 | 2.00 | |
EV/Sales |
1.03 | 0.45 | 0.62 | 0.47 | |
EV/EBITDA |
8.11 | 6.44 | 0.00 | 0.00 | |
EV/Operating CF |
(56.35) | 7.45 | 8.84 | 16.13 | |
EV/FCF |
(23.75) | 13.41 | 13.56 | 46.82 | |
Quick Ratio |
3.11 | 2.75 | 2.59 | 2.51 | |
Current Ratio |
3.62 | 3.53 | 3.52 | 3.32 | |
Net Debt/EBITDA |
(1.16) | 1.41 | 0.81 | 0.00 | |
Debt/Assets |
2.14% | 2.38% | 2.66% | 2.81% | |
Debt/Equity |
0.04 | 0.05 | 0.07 | 0.09 | |
Asset Turnover |
1.03 | 1.04 | 1.05 | 0.80 | |
Operating CF/Net income |
1.12 | (0.38) | 0.32 | 0.57 | |
Capex/Depreciation |
(0.66) | (0.25) | (0.17) | 0.00 | |
Research and Development Expense of Revenue |
4.56% | 40.72% | 41.82% | 17.51% | |
Selling, General and Administrative Expense of Revenue |
44.40% | 175.10% | 123.33% | 99.19% | |
Intangible Assets out of Total Assets |
0.06 | 0.06 | 0.08 | 0.09 | |
Share Based Compensation of Revenue |
1.92% | 9.77% | 6.98% | 6.17% | |
Graham Net Nets |
0.10 | (0.02) | (0.19) | (0.52) | |
Graham Number |
2.19 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
1.74% | (7.59%) | (34.98%) | (88.32%) | |
Free Cash Flow Yield |
(3.73%) | 5.64% | 6.66% | 2.01% | |
Revenue per Share |
1.78 | 0.29 | 0.34 | 0.35 | |
Operating CF per Share |
0.31 | 0.17 | (0.25) | (0.14) | |
Capex per Share |
(0.04) | (0.02) | (0.01) | 0.02 | |
Free Cash Flow per Share |
0.27 | 0.14 | (0.25) | (0.13) | |
Cash per Share |
0.74 | 0.72 | 0.36 | 0.21 | |
Shareholders Equity per Share |
2.37 | 1.91 | 1.15 | 0.93 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.37 | 1.91 | 1.15 | 0.93 | |
Free Cash Flow |
34.77 | 17.98 | (32.75) | (16.45) | |
Working Capital |
262.06 | 192.48 | 143.34 | 110.48 | |
Capital Expenditures |
(4.65) | (3.15) | (1.10) | 2.15 | |
Net Current Asset Value |
63.59 | (6.94) | (57.88) | (91.04) | |
EV/EBIT |
13.00 | 89.88 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.08 | 0.03 | (0.05) | |
Price to Operating Income |
14.69 | 118.82 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
163.66 | 110.11 | 110.66 | 130.74 | |
Average Payables |
30.43 | 26.64 | 29.51 | 31.35 | |
Average Inventory |
27.92 | 28.88 | 31.16 | 33.13 | |
Average Assets |
548.31 | 493.69 | 433.79 | 439.37 | |
Average Common Equity |
281.51 | 243.73 | 190.76 | 187.43 |
Columns are period end dates · fundamentals updated 5 Nov 2026